The Bank of Nova Scotia has taken a significant step in its financial strategy by filing a preliminary pricing supplement for callable contingent coupon barrier notes due November 29, 2030. This filing, submitted on November 12, 2026, highlights the bank's ongoing efforts to diversify its funding sources and manage its investment risks effectively.
These notes will be linked to the performance of major stock indices, including the Dow Jones Industrial Average, the Russell 2000, and the S&P 500. This approach allows the bank to offer investors a product that is both innovative and reflective of market conditions.
Background
The Bank of Nova Scotia, also known by its ticker symbol BNS, operates under the SIC code 6022, classified as a state commercial bank. The bank is headquartered in Toronto, Canada, and is listed on the New York Stock Exchange (NYSE). Recent filings include multiple 424B2 forms, indicating ongoing activity in capital markets.
What the Filing Says
The filing states, "The information in this Preliminary Pricing Supplement is not complete and may be changed. We may not sell these Notes until the Pricing Supplement is delivered in final form." This highlights that the notes are still in the preliminary stages and subject to finalization.
Impact
The issuance of these notes may attract a variety of investors, particularly those interested in market-linked securities. The bank's decision to offer these notes reflects a broader trend within the state commercial banking industry, where institutions are increasingly looking for innovative ways to engage with investors and manage risk. The performance of these notes will be closely watched, as they are tied to major stock indices.
What's Next
Further details regarding the final pricing and terms of the notes are expected to be released in subsequent filings. The filing does not specify what happens next.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










